Microneedling with different treatments for hair loss
Comparative Study of Combined Microneedling With Either 1% Lactic Acid Solution or Vitamin D3 or Triamcinolone Acetonide in The Treatment of Alopecia Areata
This study is testing whether microneedling combined with different treatments can help people with alopecia areata grow their hair back.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 88 (estimated) |
| Ages | 16 Years and up |
| Sex | All |
| Sponsor | Zagazig University Government |
| Drugs / interventions | immunotherapy, methotrexate |
| Locations | 1 site (Zagazig) |
| Trial ID | NCT06327581 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the effectiveness of microneedling combined with various treatments—1% lactic acid, vitamin D3, and triamcinolone acetonide—in patients with alopecia areata. Participants will undergo microneedling sessions every two weeks for up to six sessions, with the aim of stimulating hair regrowth. The study will compare the outcomes of each treatment group to determine which combination is most effective in promoting hair restoration. Photographic documentation will be used to assess changes in hair growth throughout the treatment period.
Who should consider this trial
Good fit: Ideal candidates are individuals aged 16 and older with localized patchy alopecia areata.
Not a fit: Patients with alopecia totalis, universalis, or those who have received recent treatments for alopecia may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could provide a new effective treatment option for patients suffering from alopecia areata.
How similar studies have performed: While there have been studies on microneedling for hair loss, the specific combinations being tested in this trial are novel and not widely explored.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * · Age ≥ 16 years old with localized patchy AA (up to 6 cm in diameter). * Patients of both sexes * Willing to participate in the study and to sign an informed consent. Exclusion Criteria: * · Patients who received systemic or topical treatment for AA in the last 3 months prior to the start of the study * Patients with Alopecia totalis, universalis, ophiasis, or sisaipho * Pregnant or lactating females * Patients who had bleeding or coagulation disorders * Immunocompromised patients * Patients with known history of hypersensitivity to vit D * Patients taking vitamin D supplements in the last 6 months.
Where this trial is running
Zagazig
- Rana Ehab — Zagazig, Egypt (Recruiting)
Study contacts
- Principal investigator: rana ehab, md — Zagazig University
- Study coordinator: rana ehab hamed ehab, md
- Email: ranaehab015@gmail.com
- Phone: 0201000896453
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.